Aldeyra Therapeutics, Inc.
NASDAQ:ALDXBiotechnology
+$0.06 today
- Market cap
- $54.28M
- Beta
- 1.19
- P/E (TTM)
- -4.2
- EPS (TTM)
- -$0.45
Volume 1.45M
Average 2.13M
Returns on capital
Aldeyra Therapeutics, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-76.5%
avg -62.0%
ROIC
-59.0%
avg -54.2%
ROA
-47.0%
avg -47.2%
Analysis
ROA is currently the strongest return metric at -47.0% versus its period average of -47.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Todd C. Brady | Chief Executive Officer, President & Director | USD 903K | 54 | 1.72M | 2.85% |
Michael Alfieri | Head of Finance and Principal Financial & Accounting Officer | USD 243.99K | 61 | 7.50K | 0.01% |
Laura Nichols | Operations Manager | — | — | — | — |
Adam Lazorchak | Director of Translational Sciences & Non-Clinical Development | — | — | — | — |
David Burke | Head of Investor Relations | — | — | — | — |
Compensation is shown in the reported currency; data updated Oct 3, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jun 3, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
3
$523,550.00
Sells
0
$0.00
Net Transaction Value
+$523,550.00
Net buying
Most Active
Brady Todd C
1 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Jun 3, 26Jun 3, 2026 | Brady Todd C Direct | Buy | $418.5K$418,450.00 |
| Mar 19, 26Mar 19, 2026 | DOUGLAS RICHARD Direct | Buy | $98K$98,000.00 |
| Mar 18, 26Mar 18, 2026 | Alfieri Michael Direct | Buy | $7.1K$7,100.00 |
Summary
Insiders reported 3 buys worth $523,550.00 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $523,550.00. Brady Todd C was the most active insider with 1 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Aldeyra Therapeutics, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about ALDX's management, answered from reported figures.
Who manages ALDX?
Aldeyra Therapeutics, Inc. (ALDX) lists 5 active executives. The top listed executive is Laura Nichols, Operations Manager.
Are ALDX insiders buying or selling?
Recent insider activity shows net buying of $73.32M.
Continue the stock analysis
Jump to another research area for this company.